Dr. Juho Jalkanen, MD, Ph.D. - CEO, Faron Pharmaceuticals - Tackling Cancers Via Novel Immunotherapies

Dr. Juho Jalkanen, M.D., Ph.D. is CEO and Founder of Faron Pharmaceuticals ( https://faron.com/ ), is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The Company’s lead asset bexmarilimab is currently being investigated in clinical trials as a potential therapy for patients with hematological cancers, with an initial focus on higher-risk myelodysplastic syndrome (HR MDS), in combination with other standard treatments.

Dr. Jalkanen an experienced biopharmaceutical industry executive with extensive leadership experience across key functional areas including operations, business development, clinical development, medical and regulatory affairs.   

Dr. Jalkanen earned a Master´s degree in economics and business administration from the Turku School of Economics and both his M.D. and Ph.D. degrees from the University of Turku. He is a fully licensed general practitioner and specialist in vascular surgery.

#JuhoJalkanen #FaronPharmaceuticals #Bexmarilimab #MyelodysplasticSyndrome #HematologicalCancers #HematologicalMalignancies #BloodCancer #AcuteMyeloidLeukemia #Clever1 #Macrophages #Oncology #Immunooncology #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research